4D Molecular Therapeutics FDMT Current ratio

Current ratio at other companies

Eli LillyLLY

1.4×+0.1×

Regeneron PharmaceuticalsREGN

3.3×-1.3×

Vertex PharmaceuticalsVRTX

3.2×+0.7×

EyePoint, Inc.EYPT

4.5×-3.5×

AbbVieABBV

0.8×0.0×

RegenxbioRGNX

2.9×-0.3×

FAQ

What is 4D Molecular Therapeutics's current ratio?

4D Molecular Therapeutics (FDMT) reported current ratio of 9.3× in Q1 2026.

How has 4D Molecular Therapeutics's current ratio changed year-over-year?

4D Molecular Therapeutics's current ratio decreased by 24.5% year-over-year, from 12.4× to 9.3×.

What is the long-term trend for 4D Molecular Therapeutics's current ratio?

Over 5 years (2020 to 2025), 4D Molecular Therapeutics's current ratio has grown at a -11.1% compound annual growth rate (CAGR), from 16.9× to 9.4×.

What does current ratio mean?

Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.